Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding

Pharmacogenomics

Volumn 13, Issue 13, 2012, Pages 1501-1522

  Olagunju, Adeniyi ^a,b   Owen, Andrew ^b   Cressey, Tim R ^c,d,e  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

antiretrovirals; drug transporters; highly active antiretroviral therapy; HIV; pregnancy; prevention of mother to child transmission

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

AREA UNDER THE CURVE; BREAST FEEDING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME SPECIFICITY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; LIPODYSTROPHY; LOW DRUG DOSE; MENTAL DISEASE; NONHUMAN; PHARMACOGENETICS; PHYSICAL CHEMISTRY; PREGNANCY; RECOMMENDED DRUG DOSE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN ALLERGY; STOMACH EMPTYING; STOMACH PH; TISSUE DISTRIBUTION; TRANSCRIPTION REGULATION; VERTICAL TRANSMISSION;

ANTI-HIV AGENTS; BREAST FEEDING; FEMALE; GENETIC ASSOCIATION STUDIES; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MATERNAL-FETAL EXCHANGE; MODELS, BIOLOGICAL; PHARMACOGENETICS; PLACENTA; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84867567023     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.138     Document Type: Review

References (194)

1. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 283(9), 1175-1182 (2000)
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331(18), 1173-1180 (1994)
3. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354(9181), 795-802 (1999)
4. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med. 351(3), 217-228 (2004)
5. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 22(2), 289-299 (2008)
6. Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N. Engl. J. Med. 362(24), 2271-2281 (2010)
7. de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect. Dis. 11(3), 171-180 (2011)
8. Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N. Engl. J. Med. 362(24), 2282-2294 (2010)
9. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin. Pharmacokinet. 43(15), 1071-1087 (2004)
10. Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect. Genet. Evol. 7(2), 333-342 (2007)
11. Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res. 85(1), 190-200 (2010)
12. Lubomirov R, Colombo S, di Iulio J, et al. Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J. Infect. Dis 203(2), 246-257 (2011)
13. Wyen C, Hendra H, Siccardi M, et al. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J. Antimicrob. Chemother. 66(9), 2092-2098 (2011)
14. Dunlop W. Serial changes in renal haemodynamics during normal human pregnancy. Br. J. Obstet. Gynaecol. 88(1), 1-9 (1981)
15. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am. J. Obstet. Gynecol. 192(2), 633-639 (2005)
16. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin. Pharmacokinet. 44(10), 989-1008 (2005)
17. Tirona RG, Kim RB. Nuclear receptors and drug disposition gene regulation. J. Pharm. Sci. 94(6), 1169-1186 (2005)
18. Faucette SR, Sueyoshi T, Smith CM, et al. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J. Pharmacol. Exp. Ther. 317(3), 1200-1209 (2006)
19. Fahmi OA, Kish M, Boldt S, et al. Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymes. Drug Metab. Dispos. 38(9), 1605-1611 (2010)
20. Morris CA, Onyamboko MA, Capparelli E, et al. Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Malar. J. 10, 114 (2011)
21. Badger TM, Hidestrand M, Shankar K, et al. The effects of pregnancy on ethanol clearance. Life Sci. 77(17), 2111-2126 (2005)
22. Else LJ, Taylor S, Back DJ, et al. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). Antivir. Ther. 16(8), 1139-1147 (2011)
23. Watts DH. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr. HIV/AIDS Rep. 4(3), 135-140 (2007)
24. Ross AC, Leong T, Avery A, et al. Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress. HIV Med. 13(2), 98-106 (2012)
25. Evseenko D, Paxton JW, Keelan JA. Active transport across the human placenta: impact on drug efficacy and toxicity. Expert Opin Drug Metab. Toxicol. 2(1), 51-69 (2006)
26. Gulati A, Gerk PM. Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy. J. Pharm. Sci. 98(7), 2317-2335 (2009)
27. Iqbal M, Audette MC, Petropoulos S, et al. Placental drug transporters and their role in fetal protection. Placenta 33(3), 137-142 (2012)
28. Ieiri I. Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2). Drug Metab. Pharmacokinet. 27(1), 85-105 (2012)
29. Griffin L, Annaert P, Brouwer KL. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J. Pharm. Sci. 100(9), 3636-3654 (2011)
30. Moss DM, Kwan WS, Liptrott NJ, et al. Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob. Agents Chemother. 55(2), 879-887 (2011)
31. Pal D, Kwatra D, Minocha M, et al. Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals. Life Sci. 88(21-22), 959-971 (2011)
32. Shitara Y. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab. Pharmacokinet. 26(3), 220-227 (2011)
33. Kis O, Robillard K, Chan GN, et al. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol. Sci. 31(1), 22-35 (2010)
34. Rubinchik-Stern M, Eyal S. Drug interactions at the human placenta: what is the evidence?. Front. Pharmacol. 3, 126 (2012)
35. Bazzoli C, Jullien V, Le Tiec C, et al. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin. Pharmacokinet. 49(1), 17-45 (2010)
36. Veal GJ, Back DJ. Metabolism of zidovudine. Gen. Pharmacol. 26(7), 1469-1475 (1995)
37. Sperling RS, Roboz J, Dische R, et al. Zidovudine pharmacokinetics during pregnancy. Am. J. Perinatol. 9(4), 247-249 (1992)
38. O'Sullivan MJ, Boyer PJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am. J. Obstet. Gynecol. 168(5), 1510-1516 (1993)
39. Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J. Infect. Dis 178(5), 1327-1333 (1998)
40. Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J. Infect. Dis 163(2), 226-232 (1991)
41. Cressey TR, Leenasirimakul P, Jourdain G, et al. Intensive pharmacokinetics of zidovudine 200 mg twice daily in HIV-1-infected patients weighing less than 60 kg on highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 42(3), 387-389 (2006)
42. Duncombe C, Kerr SJ, Liddy J, et al. Efficacy and tolerability of zidovudine 200 mg twice a day as part of combination antiretroviral therapy for 96 weeks. J. Acquir. Immune Defic. Syndr. 54(5), e19-e20 (2010)
43. Anderson PL, Lamba J, Aquilante CL, et al. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J. Acquir. Immune Defic. Syndr. 42(4), 441-449 (2006)
44. Sai Y, Nishimura T, Shimpo S, et al. Characterization of the mechanism of zidovudine uptake by rat conditionally immortalized syncytiotrophoblast cell line TR-TBT. Pharm. Res. 25(7), 1647-1653 (2008)
45. Wade NA, Unadkat JD, Huang S, et al. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332. J. Infect. Dis 190(12), 2167-2174 (2004)
46. Wangsomboonsiri W, Mahasirimongkol S, Chantarangsu S, et al. Association between HLA?B, 4001 and lipodystrophy among HIV-infected patients from Thailand who received a stavudine-containing antiretroviral regimen. Clin. Infect. Dis 50(4), 597-604 (2010)
47. Best BM, Mirochnick M, Capparelli EV, et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS 20(4), 553-560 (2006)
48. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23(10), 1603-1614 (2001)
49. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA?B, 5701, HLA?DR7, and HLA?DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308), 727-732 (2002)
50. Mallal S, Phillips E, Carosi G, et al. HLA?B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008)
51. Benaboud S, Treluyer JM, Urien S, et al. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob. Agents Chemother. 56(2), 776-782 (2012)
52. Mandelbrot L, Peytavin G, Firtion G, et al. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women. Am. J. Obstet. Gynecol. 184(2), 153-158 (2001)
53. Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J. Infect. Dis 192(5), 720-727 (2005)
54. Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob. Agents Chemother. 53(3), 1170-1176 (2009)
55. Jung N, Lehmann C, Rubbert A, et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab. Dispos. 36(8), 1616-1623 (2008)
56. Minuesa G, Volk C, Molina-Arcas M, et al. Transport of lamivudine [(-)-beta-L-2,3-dideoxy-3-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J. Pharmacol. Exp. Ther. 329(1), 252-261 (2009)
57. Bleasby K, Castle JC, Roberts CJ, et al. Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition. Xenobiotica 36(10-11), 963-988 (2006)
58. Choi MK, Song IS. Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm. Drug Dispos. 33(3), 170-178 (2012)
59. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354(9184), 1084-1089 (1999)
60. Divi RL, Walker VE, Wade NA, et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to combivir. AIDS 18(7), 1013-1021 (2004)
61. Kallianpur AR, Hulgan T. Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. Pharmacogenomics 10(4), 623-637 (2009)
62. Canter JA, Robbins GK, Selph D, et al. African mitochondrial DNA subhaplogroups and peripheral neuropathy during antiretroviral therapy. J. Infect. Dis 201(11), 1703-1707 (2010)
63. Stek AM, Best BM, Luo W, et al. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med. 13(4), 226-235 (2011)
64. Benaboud S, Pruvost A, Coffie PA, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob. Agents Chemother. 55(3), 1315-1317 (2011)
65. Bousquet L, Pruvost A, Didier N, et al. Emtricitabine: inhibitor and substrate of multidrug resistance associated protein. Eur. J. Pharm. Sci. 35(4), 247-256 (2008)
66. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 43(9), 595-612 (2004)
67. Burchett S, Best B, Mirochnick M, et al. Tenofovir pharmacokinetics during pregnancy, at delivery and postpartum. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA, USA, 25-28 February 2007 (Abstract 738b)
68. Colbers A, Taylor G, Molto J, et al. A comparison of the pharmacokinetics of tenofovir during pregnancy and postpartum. Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain, 16-18 April 2012.
69. Benaboud S, Hirt D, Launay O, et al. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob. Agents Chemother. 56(2), 857-862 (2012)
70. Best BM, Letendre SL, Koopmans P, et al. Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J. Acquir. Immune Defic. Syndr. 59(4), 376-381 (2012)
71. Uwai Y, Ida H, Tsuji Y, et al. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm. Res. 24(4), 811-815 (2007)
72. Pushpakom SP, Liptrott NJ, Rodriguez-Novoa S, et al. Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J. Infect. Dis 204(1), 145-153 (2011)
73. Alebouyeh M, Takeda M, Onozato ML, et al. Expression of human organic anion transporters in the choroid plexus and their interactions with neurotransmitter metabolites. J. Pharmacol. Sci. 93(4), 430-436 (2003)
74. Nahata MC, Brady MT. Pharmacokinetics of fluconazole after oral administration in children with human immunodeficiency virus infection. Eur. J Clin Pharmacol. 48(3-4), 291-293 (1995)
75. Leggas M, Adachi M, Scheffer GL, et al. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol. Cell. Biol. 24(17), 7612-7621 (2004)
76. Gibbs JE, Thomas SA. The distribution of the anti-HIV drug, 23-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors. J. Neurochem. 80(3), 392-404 (2002)
77. Anthonypillai C, Gibbs JE, Thomas SA. The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses. Cerebrospinal Fluid Res. 3, 1 (2006)
78. Kiser JJ, Aquilante CL, Anderson PL, et al. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J. Acquir. Immune Defic. Syndr. 47(3), 298-303 (2008)
79. Cihlar T, Ho ES, Lin DC, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20(4-7), 641-648 (2001)
80. Mallants R, Van Oosterwyck K, Van Vaeck L, et al. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica 35(10-11), 1055-1066 (2005)
81. Imaoka T, Kusuhara H, Adachi M, et al. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol. Pharmacol. 71(2), 619-627 (2007)
82. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin. Infect. Dis 48(11), e108-e116 (2009)
83. Rodriguez-Novoa S, Labarga P, D'Avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS 24(7), 1064-1066 (2010)
84. Viramune® Tablets, Viramune® Oral Suspension, package insert. Boehringer-Ingelheim Pharmaceuticals Inc., CT, USA.
85. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J. Acquir. Immune Defic. Syndr. 38(3), 283-288 (2005)
86. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 351(3), 229-240 (2004)
87. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med. 6(10), e1000172 (2009)
88. Van Dyke RB, Ngo-Giang-Huong N, Shapiro DE, et al. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. Clin. Infect. Dis 54(2), 285-293 (2012)
89. Chantarangsu S, Cressey TR, Mahasirimongkol S, et al. Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women. J. Antimicrob. Chemother. 64(6), 1265-1273 (2009)
90. Capparelli EV, Aweeka F, Hitti J, et al. Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Med. 9(4), 214-220 (2008)
91. Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, et al. Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. J. Acquir. Immune Defic. Syndr. 55(3), 345-350 (2010)
92. von Hentig N, Carlebach A, Gute P, et al. A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br. J. Clin. Pharmacol. 62(5), 552-559 (2006)
93. Penzak SR, Kabuye G, Mugyenyi P, et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med. 8(2), 86-91 (2007)
94. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J. Antimicrob. Chemother. 61(4), 914-918 (2008)
95. Brown KC, Hosseinipour MC, Hoskins JM, et al. Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics 13(1), 113-121 (2012)
96. Liptrott NJ, Pushpakom S, Wyen C, et al. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet. Genomics 22(1), 10-19 (2012)
97. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J. Acquir. Immune Defic. Syndr. 36(3), 772-776 (2004)
98. Phanuphak N, Apornpong T, Teeratakulpisarn S, et al. Nevirapine- associated toxicity in HIV-infected Thai men and women, including pregnant women. HIV Med. 8(6), 357-366 (2007)
99. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLAB, 3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet. Genomics 19(2), 139-146 (2009)
100. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin. Infect. Dis 53(4), 341-348 (2011)
101. Ellis JC, L'homme RF, Ewings FM, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir. Ther. 12(2), 253-260 (2007)
102. Minniear TD, Zeh C, Polle N, et al. Rash, hepatotoxicity and hyperbilirubinemia among kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission. Pediatr. Infect. Dis. J. doi:10.1097/INF.0b013e318267ef6a
103. Fundaro C, Genovese O, Rendeli C, et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 16(2), 299-300 (2002)
104. Bussmann H, Wester CW, Wester CN, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J. Acquir. Immune Defic. Syndr. 45(3), 269-273 (2007)
105. Bera E, McCausland K, Nonkwelo R, et al. Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital. AIDS 24(2), 283-289 (2010)
106. Ford N, Mofenson L, Kranzer K, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 24(10), 1461-1470 (2010)
107. Ekouevi DK, Coffie PA, Ouattara E, et al. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA west Africa and ANRS databases, Abidjan, Cote d'Ivoire. J. Acquir. Immune Defic. Syndr. 56(2), 183-187 (2011)
108. Cressey TR, Stek A, Capparelli E, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J. Acquir. Immune Defic. Syndr. 59(3), 245-252 (2012)
109. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306(1), 287-300 (2003)
110. di Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics 19(4), 300-309 (2009)
111. Ogburn ET, Jones DR, Masters AR, et al. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 38(7), 1218-1229 (2010)
112. Bae SK, Jeong YJ, Lee C, et al. Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites. Xenobiotica 41(6), 437-444 (2011)
113. Kwara A, Lartey M, Sagoe KW, et al. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23(16), 2101-2106 (2009)
114. Kwara A, Lartey M, Sagoe KW, et al. CYP2B6 (c.516G->T) and CYP2A6 (, 9B and/or , 17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br. J. Clin. Pharmacol. 67(4), 427-436 (2009)
115. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15(1), 1-5 (2005)
116. Schneider S, Peltier A, Gras A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J. Acquir. Immune Defic. Syndr. 48(4), 450-454 (2008)
117. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15(1), 71-75 (2001)
118. Peroni RN, Di Gennaro SS, Hocht C, et al. Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat. Biochem. Pharmacol. 82(9), 1227-1233 (2011)
119. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61(8), 3458-3464 (2001)
120. Jonker JW, Merino G, Musters S, et al. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat. Med. 11(2), 127-129 (2005)
121. Hahnova-Cygalova L, Ceckova M, Staud F. Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy. Drug Metab. Rev. 43(1), 53-68 (2011)
122. Izurieta P, Kakuda TN, Feys C, et al. Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women. HIV Med. 12(4), 257-258 (2011)
123. Yanakakis LJ, Bumpus NN. Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab. Dispos. 40(4), 803-814 (2012)
124. McGready R, Stepniewska K, Seaton E, et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. Eur. J. Clin. Pharmacol. 59(7), 553-557 (2003)
125. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354-362 (2009)
126. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121(4), 512-518 (2010)
127. Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277(1), 423-431 (1996)
128. van der Sandt IC, Vos CM, Nabulsi L, et al. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS 15(4), 483-491 (2001)
129. Janneh O, Bray PG, Jones E, et al. Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes. J. Antimicrob. Chemother. 65(5), 906-916 (2010)
130. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS 20(15), 1931-1939 (2006)
131. Else LJ, Douglas M, Dickinson L, et al. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob. Agents Chemother. 56(2), 816-824 (2012)
132. Cressey TR, Jourdain G, Rawangban B, et al. Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS 24(14), 2193-2200 (2010)
133. Calza L, Manfredi R, Trapani F, et al. Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy. Scand. J. Infect. Dis 44(5), 381-387 (2012)
134. Ramautarsing RA, van der Lugt J, Gorowara M, et al. Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy. AIDS 25(10), 1299-1303 (2011)
135. Lambert JS, Else LJ, Jackson V, et al. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy. HIV Med. 12(3), 166-173 (2011)
136. Best BM, Stek AM, Mirochnick M, et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J. Acquir. Immune Defic. Syndr. 54(4), 381-388 (2010)
137. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet. Genomics 20(2), 112-120 (2010)
138. Schipani A, Egan D, Dickinson L, et al. Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antivir. Ther. 17(5), 861-868 (2012)
139. Rezk NL, White N, Bridges AS, et al. Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Ther. Drug. Monit. 30(5), 611-619 (2008)
140. Ripamonti D, Cattaneo D, Maggiolo F, et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 21(18), 2409-2415 (2007)
141. Mirochnick M, Best BM, Stek AM, et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J. Acquir. Immune Defic. Syndr. 56(5), 412-419 (2011)
142. Mirochnick M, Stek A, Capparelli E, et al. Pharmacokinetics of increased dose atazanavir with and without tenofovir during pregnancy. Presented at: 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, FL, USA, 13-15 April 2011.
143. Anderson PL, Aquilante CL, Gardner EM, et al. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J. Antimicrob. Chemother. 64(5), 1071-1079 (2009)
144. Siccardi M, D'Avolio A, Baietto L, et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C
145. Schipani A, Siccardi M, D'Avolio A, et al. Population pharmacokinetic modeling of the association between 63396C
146. Kile DA,Mawhinney S, Aquilante CL, et al. A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res. Hum. Retroviruses doi:10.1089/aid.2011.0378 2012 (Epub ahead of print)
147. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21(1), 41-46 (2007)
148. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis 192(8), 1381-1386 (2005)
149. Huang MJ, Kua KE, Teng HC, et al. Risk factors for severe hyperbilirubinemia in neonates. Pediatric Res. 56(5), 682-689 (2004)
150. Mandelbrot L, Mazy F, Floch-Tudal C, et al. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia. Eur. J. Obstet. Gynecol. Reprod. Biol. 157(1), 18-21 (2011)
151. Spencer L, Neely M, Mordwinkin N, et al. Intensive pharmacokinetics of zidovudine, lamivudine, and atazanavir and HIV-1 viral load in breast milk and plasma in HIV+ women receiving HAART. Presented at: 16th Conference on Retroviruses and Opportunistic Infections (CROI). Montréal, Canada, 8-11 February 2009 (Abstract 942)
152. Capparelli E, Best B, Stek A, et al. Pharmacokinetics of darunavir once or twice daily during and after pregnancy. Presented at: 3rd International Workshop on HIV Pediatrics. Rome, Italy, 15-16 July 2011 (Abstract P-72)
153. Capparelli E, Stek A, Best B, et al. Boosted fosamprenavir pharmacokinetics during pregnancy. Presented at: 17th Conference on Retroviruses and Opportunistic Infections (CROI). San Francisco, CA, USA, 16-19 February 2010.
154. Taylor N, Touzeau V, Geit M, et al. Raltegravir in pregnancy: a case series presentation. Int. J. STD AIDS 22(6), 358-360 (2011)
155. McKeown DA, Rosenvinge M, Donaghy S, et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 24(15), 2416-2418 (2010)
156. Best BM, Capparelli E, Stek A, et al. Raltegravir pharmacokinetics during pregnancy. Presented at: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Boston, MA, USA, 12-15 September 2010 (Abstract H-1668a)
157. Ananworanich J, Gorowara M, Avihingsanon A, et al. Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy. Antimicrob. Agents Chemother. 56(4), 1892-1898 (2012)
158. Siccardi M, D'Avolio A, Rodriguez-Novoa S, et al. Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. Ther. Drug Monit. 34(2), 232-235 (2012)
159. Hirano A, Ikemura K, Takahashi M, et al. Lack of correlation between UGT1A1, 6, , 28 genotypes, and plasma raltegravir concentrations in Japanese HIV type 1-infected patients. AIDS Res. Hum. Retroviruses 28(8), 776-779 (2011)
160. Arab-Alameddine M, Fayet-Mello A, Lubomirov R, et al. Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. Antimicrob. Agents Chemother. 56(6), 2959-2966 (2012)
161. Weizsaecker K, Kurowski M, Hoffmeister B, et al. Pharmacokinetic profile in late pregnancy and cord blood concentration of tipranavir and enfuvirtide. Int. J. STD AIDS. 22(5), 294-295 (2011)
162. Wensing AM, Boucher CA, van Kasteren M, et al. Prevention of mother-to-child transmission of drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir. AIDS 20(10), 1465-1467 (2006)
163. Sued O, Lattner J, Gun A, et al. Use of darunavir and enfuvirtide in a pregnant woman. Int. J. STD AIDS. 19(12), 866-867 (2008)
164. Madeddu G, Calia GM, Campus ML, et al. Successful prevention of multidrug resistant HIV mother-to-child transmission with enfuvirtide use in late pregnancy. Int. J. STD AIDS. 19(9), 644-645 (2008)
165. Furco A, Gosrani B, Nicholas S, et al. Successful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistance. AIDS 23(3), 434-435 (2009)
166. Cohan D, Feakins C, Wara D, et al. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. AIDS 19(9), 989-990 (2005)
167. Vincent J, Ahmed T, Eric L, et al. Favourable outcome of a pregnancy with a maraviroc-containing regimen. J. AIDS Clinic. Res. 2(6), (2011)
168. Siccardi M, D'Avolio A, Nozza S, et al. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. Pharmacogenet. Genomics 20(12), 759-765 (2010)
169. Chappuy H, Treluyer JM, Rey E, et al. Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am. J. Obstet. Gynecol. 191(2), 558-562 (2004)
170. Flynn PM, Mirochnick M, Shapiro DE, et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob. Agents Chemother. 55(12), 5914-5922 (2011)
171. Musoke P, Guay LA, Bagenda D, et al. A Phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 13(4), 479-486 (1999)
172. van Heeswijk RP, Khaliq Y, Gallicano KD, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin. Pharmacol. Ther. 76(6), 588-597 (2004)
173. Winters MA, Van Rompay KK, Kashuba AD, et al. Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques. Antimicrob. Agents Chemother. 54(10), 4059-4063 (2010)
174. Brennan-Benson P, Pakianathan M, Rice P, et al. Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. AIDS 20(2), 297-299 (2006)
175. Ripamonti D, Cattaneo D, Cortinovis M, et al. Transplacental passage of ritonavir-boosted darunavir in two pregnant women. Int. J. STD AIDS 20(3), 215-216 (2009)
176. Ciccacci C, Borgiani P, Ceffa S, et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics 11(1), 23-31 (2012)
177. Ni Z, Mao Q. ATP-binding cassette efflux transporters in human placenta. Curr. Pharm. Biotechnol. 12(4), 674-685 (2011)
178. Ellis L, Pirmohamed M, Owen A. Transport of antiretroviral drugs by ABCB5: the elusive non-nucleoside transcriptase inhibitor efflux pump?. Presented at: 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, FL, USA, 13-15 April 2011
179. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37(11), 3594-3601 (1998)
180. Huisman MT, Smit JW, Crommentuyn KM, et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16(17), 2295-2301 (2002)
181. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. 275(39), 30069-30074 (2000)
182. Moitra K, Scally M, McGee K, et al. Molecular evolutionary analysis of ABCB5: the ancestral gene is a full transporter with potentially deleterious single nucleotide polymorphisms. PloS ONE 6(1), e16318 (2011)
183. Wang H, Yan Z, Dong M, et al. Alteration in placental expression of bile acids transporters OATP1A2, OATP1B1, OATP1B3 in intrahepatic cholestasis of pregnancy. Arch. Gynecol. Obstet. 285(6), 1535-1540 (2011)
184. Kohler JJ, Hosseini SH, Green E, et al. Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters. Lab. Invest. 91(6), 852-858 (2011)
185. Xu G, Bhatnagar V, Wen G, et al. Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes [OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. Kidney Int. 68(4), 1491-1499 (2005)
186. Ugele B, St-Pierre MV, Pihusch M, et al. Characterization and identification of steroid sulfate transporters of human placenta. Am. J. Physiol. Endocrinol. Metab. 284(2), e390-e398 (2003)
187. Ugele B, Bahn A, Rex-Haffner M. Functional differences in steroid sulfate uptake of organic anion transporter 4 (OAT4) and organic anion transporting polypeptide 2B1 (OATP2B1) in human placenta. J. Steroid Biochem. Mol. Biol. 111(1-2), 1-6 (2008)
188. Alcorn J, Lu X, Moscow JA, et al. Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. J. Pharmacol. Exp. Ther. 303(2), 487-496 (2002)
189. Nies AT, Koepsell H, Winter S, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50(4), 1227-1240 (2009)
190. Saito J, Hirota T, Kikunaga N, et al. Interindividual differences in placental expression of the SLC22A2 (OCT2) gene: relationship to epigenetic variations in the 5-upstream regulatory region. J. Pharm. Sci. 100(9), 3875-3883 (2011)
191. Sata R, Ohtani H, Tsujimoto M, et al. Functional analysis of organic cation transporter 3 expressed in human placenta. J. Pharmacol. Exp. Ther. 315(2), 888-895 (2005)
192. Cressey T, Best BM, Achalapong J, et al. Effect of pregnancy on pharmacokinetics of indinavir boosted with ritonavir. Presented at: 13th International Workshop on Clinical Pharmacology of HIV Therapy. Barcelona, Spain, 16-18 April 2012 (Abstract P-37)
193. Read JS, Best BM, Stek AM, et al. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med. 9(10), 875-882 (2008)
194. Martinez-Rebollar M, Lonca M, Perez I, et al. Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women. Ther. Drug Monit. 33(6), 772-777 (2011).